Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

China's I-Mab Inks $548 Million Immunoncology Pact with Genexine

publication date: Dec 22, 2017

China's I-Mab Biopharma inked a $548 million agreement with Genexine of South Korea to in-license China rights to Genexine's immunoncology candidate, HyLeukin. I-Mab paid $12 million upfront and is responsible for the remainder in milestones, plus royalties on sales. HyLeukin uses Interleukin-7, a factor in the proliferation and homeostasis of T cells, to create the immunotherapy. Genexine is a prolific dealmaker with China pharmas -- it is a major investor in I-Mab and has forged several deals with Tasly Pharma, also an investor in I-Mab along with C-Bridge Capital. More details....

Stock Symbols: (KOSDAQ, 095700) (SHA: 600535)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.